Evaluation of whole body MRI for early detection of cancer in TP53 mutation carriers: Final results of the LIFSCREEN study.

1527Background: Li Fraumeni syndrome (LFS) is a rare cancer predisposition caused by TP53 germline mutation associated with a broad tumor spectrum making surveillance very complex. Whole body MRI (WBMRI) is an attractive strategy. The LIFSCREEN nation-wide trial was designed to evaluate the impact of adding WBMRI as a screening tool on the overall survival (OS) of LFS patients. Methods: Participants (pts) were TP53 mutation carriers, > 5 and < 71 y, with/without cancer personal history. Pt were randomized in standard surveillance arm (“A”: clinical exam, brain MRI, abdomino-pelvic US, CBC, and breast MRI/US and breast US for women over 20), or in “B” arm (A + WB diffusion MRI). Each pt repeated annually the process for at least 3 years. Acceptability and psychological impact were evaluated throughout the study. Results: 105 pts (mean age 33y [5-67]) were randomized in one of the 19 French centers. In 318 screening rounds, 24 pts presented 31 new primary cancers (NPC): 20 in A arm and 11 in B arm. 12 NPC w...